J&J and Pfizer line up in Covid-19 vaccine race      

Johnson and Johnson confirm they are planning a "robust" trial period for their Covid-19 vaccine 

Johnson and Johnson compete with Pfizer to get Covid-19 vaccine over the finish line 

As the race for a Covid-19 vaccine gets closer to the finish line, investors are parsing details of trial designs like never before as they handicap which is most likely to succeed.

Johnson & Johnson confirmed it plans to test its Covid-19 vaccine in as many as 60,000 people, twice the number of other big trials being conducted in the US. The company first posted the design for the trial on August 10, and it is set to begin in late September.